NCT00627848View on ClinicalTrials.gov

Rivastigmine in Mild Alzheimer's Disease, FMRI Study

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Alzheimer' Disease
Interventions
DRUG

rivastigmine

Acute dose 3 mg or placebo. Thereafter 1.5 mg x 2 ad 30 days and thereafter increasing the dose upto 4.5 mg x 2 according to instructions.

Trial Locations (1)

70211

Kuopio University Hospital, Kuopio

All Listed Sponsors
lead

Kuopio University Hospital

OTHER

NCT00627848 - Rivastigmine in Mild Alzheimer's Disease, FMRI Study | Biotech Hunter | Biotech Hunter